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 INTRODUCTION
Neuromuscular blocking agents are commonly used to facilitate tracheal intubation.
An ideal muscle relaxant should have rapid onset, profound relaxation of all muscles and short 
duration of action so that the patient’s own respiratory function can be restored,  should intubation 
proved to be impossible.
These requirements are best met with Succinylcholine, an ultra short acting depolarizing muscle 
relaxant. Unfortunately, succinylcholine has many  undesirable side effects, some of which may be life 
threatening.
Rocuronium bromide is a newer steroidal non-depolarizing neuromuscular blocker with a rapid 
onset and may be a suitable alternative to succinylcholine for rapid control of airway.
There is dose dependent decrease in onset time with Rocuronium and dose of Rocuronium used 
may influence the rate of onset of satisfactory intubating conditions.
Large doses of Rocuronium (more than 1mg/kg)produces ideal intubating conditions in  30-60 
seconds but the duration of action is very much prolonged.
AIM OF THE STUDY
             The aim of my study is to evaluate the intubating conditions in 60 seconds using two different 
doses of Rocuronium with suxamethonium for  intubation in children.
It is a study comparing two doses of Rocuronium (0.6mg/kg (2xED95) and 0.9mg/kg (3xED95) 
with suxamethonium 1.5mg/kg for intubation in children in 60 seconds and observed:-
1) Intubating conditions
2) Hemodynamic changes
3) Adverse effects
 PHYSIOLOGY OF NEUROMUSCULAR JUNCTION
Neuromuscular Junction (NMJ) is a synapse at which an electrical impulse travelling down a 
nerve is  converted into muscle  action potential  and contraction by chemical  transmitters.  A motor 
neuron, along with all the muscle fibres supplied by it forms a motor unit, which follows all or none 
law of contraction.
 
PARTS OF NEUROMUSCULAR JUNCTION
To  understand  the  physiological  events  occurring  during  neuromuscular  transmission  it  is 
essential to understand the anatomy of NMJ, which can be divided into,
1) Presynaptic nerve terminal
2) Synaptic cleft
3) Post Synaptic membrane-Acetylcholine receptors
4) Contractile apparatus
NEURO MUSCULAR  JUNCTION
PRESYNAPTIC NERVE TERMINAL:
Presynaptic  nerve  terminal  contains  all  the  apparatus  necessary  for  the  synthesis  of 
acetylcholine, which exists in  two forms: 20% in the soluble form in the presynaptic axoplasm and 
80% in vesicles, which can be further, divided into a readily available pool and a reserve pool. The 
vesicles are 40-50nm in diameter each containing 1000-10000 molecules of Ach. The walls of the 
vesicles  contain synapsins  that  help in  anchoring the vesicle  to  the cytoskeletal  framework of  the 
axoplasm.
At the membrane facing the synaptic cleft, there is an electron dense patch, the active zone, 
around which the readily available pool of Ach vesicles are arranged. Electron microscopy shows small 
pores  between the  vesicles  at  the  active  zone.  These  are  the  calcium channels.  The  terminal  also 
contains sodium and potassium channels.
The  nerve  endings  on  fast  muscles  are  longer  and  more  complicated  than  those  on  slow 
muscles. The reason for this is unclear. These differences in the nerve endings on the muscle surfaces 
may play a role in the differences in the response to muscle relaxants of fast and slow muscles.
SYNAPTIC CLEFT:
It is 20nm wide space between the nerve terminal and the muscle end plate. The nerve and 
muscles are held in tight alignment by protein filaments, which span the cleft between nerve and end 
plate. The muscle surface is heavily corrugated with deep invaginations of the junctional cleft,  the 
primary clefts and the secondary clefts, between the folds in muscle membrane. The shoulders of the 
folds are densely populated with acetylcholine receptors about 5 million of them in each junction. 
These receptors are spares in the depths between the folds. Instead these deep areas contain sodium 
channels. These sodium channels have two component gates, voltage and time dependent gates.
POST SYNAPTIC MEMBRANE – Acetyl Choline RECEPTORS:
The  Ach  receptors  at  the  NMJ  are  nicotinic  and  can  be  divided  into  pre  synaptic  and 
postsynaptic. The latter are further divided into junctional and extrajunctional.
The Ach receptor is a pentameric transmembrane spaning protein. The 5 protein subunits are 
arranged in the form of a rosette with a central ion channel. The molecular weight of the receptor is 
250000-270000.  The  mature  junctional  receptor  contains  2  α,  β, δ and  ε .  The  immature  extra 
junctional receptor contains 2 α,  β, δ and γ  which proliferate in abnormal conditions. The extracellular 
surface of the alpha subunits contains high affinity Ach binding sites.
CONTRACTILE APPARATUS:
The contractile apparatus of the muscle is formed by the myofilament comprising the thin actin 
filaments and thick myosin filaments, along with tropomyosin, troponin I, T and C. Tropomyosin is 
attached to the myosin binding site of actin.
The myofilaments combine to form myofibrils.  The muscle plasma membrane, the sarcolemma 
invaginates to form T-tubules which lies in close association with sarcoplasmic reticulum which is a 
collection of sacs and tubules acting as a reservoir for calcium.
MECHANISM OF NEUROMUSCULAR TRANSMISSION
MECHANISM OF ACETYL CHOLINE RELEASE:
An action potential traveling down the nerve causes the sodium channels in the presynaptic 
nerve terminal to open, leading to sodium influx. The change in voltage produced by such an influx 
activates  the calcium channels, which open up leading to calcium entry. Calcium mediated activation 
of calcium-calmodulin dependent protein kinases lead to phosphorylation of synapsins in the vesicle 
wall, causing the vesicles to break away from the cytoskeletal framework. The vesicles then attach to 
the active zones  with release of  Ach molecules.  Each nerve impulse causes the release of  around 
100-400 quanta of Ach. Activation of around 20-25% receptors is essential for impulse transmission.
BINDING OF ACETYL CHOLINE TO RECEPTOR:
The Ach molecule released into the synaptic cleft binds to the alpha subunit. Binding of Ach to 
both  the  alpha  subunits  activates  the  receptor,  leading  to  configurational  changes  in  the  receptor 
structure and opening up of ion channels. This leads to depolarization of the muscle end plate which 
when  of  a  sufficient  magnitude   causes  a  wave  of  depolarization  to  spread  across  the  muscle 
sarcolemma by means of activation of  the voltage dependent  gates  of the sodium channels  in the 
perijunctional zones. This depolarization wave moving down the T tubule causes release of calcium 
from sarcoplasmic reticulum. Calcium so released binds to troponin C causing tropomyosin to move 
and expose the myosin binding sites of actin leading to the formation of cross linkage of actin and 
myosin  heads.  They slide  over  each  other  leading  to  shortening  of  the  myofilaments  and  muscle 
contraction.
DISSOCIATION OF ACETYL CHOLINE FROM RECEPTOR:
The  Ach  molecule  remains  attached  to  its  receptor  for  a  very short  period  of  less  than  1 
millisecond,  after  which  it  dissociates  from  the  receptor  and  is  hydrolysed  by  the  enzyme 
acetylcholinesterase. It hydrolyses Ach into acetate and choline,  the choline being taken up by the 
presynaptic nerve terminal and used for further Ach synthesis.
MECHANISM OF NON-DEPOLARISING BLOCKAGE
Non-depolarizing muscle relaxants are drugs having an affinity for the alpha subunits of the 
acetylcholine receptors mainly at the postjunctional nicotinic receptors and also at the prejunctional 
sites of nerve ending. Binding of these relaxants to the alpha subunits of  Ach receptors can not open 
the ion channel and it also prevents further binding of Ach molecule. So an action potential is not 
developed and there is no contraction of muscle fibre.  This competitive blockade of Ach receptor is 
termed as non-depolarising blockade.
MARGIN OF SAFETY:
Atleast 75% of receptors must be occupied before neuromuscular transmission is impaired and 
if more than 90% of the receptors are occupied, transmission fails.
CHARACTERISTIC FEATURES:
1) Slow onset to maximal effect and slow recovery compared to succinylcholine.
2) The  central  muscles  like  the  diaphragm,  larynx,  masseter,  orbicularis  oculi  tend  to  be 
affected earlier  and recover from the block sooner than those of the peripheral  muscles 
(adductor pollicis) probably as a result of preferential perfusion.
3) Presence of fade and post tetatnic potentiation.
4) Despite flaccid paralysis, the muscles are still able to respond to direct stimulation.
5) The muscle block is reversed pharmacologically by anticholinesterase drugs.
6) Low potency drugs like rocuronium and rapacuronium have rapid onset of action while 
potent relaxants like doxacurium and pancuronium have relatively slower onset of action 
and a longer duration of action.
MECHANISM OF DEPOLARISING NEUROMUSCULAR BLOCKADE
Depolarising agents like suxamethonium cause initial depolarization of the endplate due to their 
acetylcholine like actions, which is transduced into a muscle contraction, but repeated action on the 
receptor leads to a persistent depolarizing voltage.
This influences the sodium channels in the vicinity of the endplate,  the perijunctional area, 
where the transmembrane voltage causes the voltage gates to remain open and the time gates to remain 
closed, thereby preventing further ion entry through the channel. Further spread of the depolarization is 
arrested, and it remains confined to the endplate only. With the progress of depolarization arrested, the 
channels in the remainder of the muscle are freed of the depolarizing influence and return to their 
resting state. Thus 3 discrete zones can be delineated namely.
1) Endplate – persistently depolarized.
2) Perijunctional area – Sodium channels still under the depolarizing influence are frozen 
in closed state.
3) Rest of the muscle – Relaxed, as sodium channels return to resting state.
PHARMACOLOGY
ROCURONIUM BROMIDE
Originally synthesized and studied in the Organon Teknika Laboratories as ORG 9426. 
Introduced into clinical practice in 1994.
CHEMISTRY:
Rocuronium is a steroidal muscle relaxant of intermediate duration. It is the 2 – morpholino, 3 – 
hydroxy, 16-N-allyl-pyrrolidino derivative of vecuronium.
1- (2 β, 3α,  5α,  16β,  17β)  - 17 - (acetyloxy)  - 3 – hydroxy- 2-(4 morpholinyl ) - androstan – 
16 – yl) – 1 – ( 2 -  Propenyl ) pyrrolidium bromide.
MOLECULAR STRUCTURE:
PRESENTATION:
As a clear colourless solution containing 10 mg/ml of Rocuronium bromide. It is available in 
5ml & 10ml  Vials.
ROUTES OF ADMINISTRATION:
Intravenous. Intramuscular.
Doses:-
ED95 : 0.3 mg / kg
Intubation at 60 – 90 sec : 0.6 – 0.9 mg / kg
Relaxation (N2O / O2) : 03 – 04 mg / kg
Relaxation (Vapour) : 0.2 – 0.3 mg / kg
Maintenance : 0.1 – 0.15 mg / kg
Infusion : 8 – 12 microg / kg / min.
ONSET OF ACTION:
89 + / - 36.9 Seconds
DURATION OF ACTION:
2 x ED95 – 27.3 +/- 8.2 min.
3 x ED95 – 53.0 +/- 15.0 min
RECOVERY INDEX:
8 – 17 Minutes
If  given  by  intramuscular  injection  into  the  deltoid  (1  mg/kg  in  infants  and  1.8mg/kg  in 
children), it permits intubation in approximately 3 minutes.
PHARMACOKINETICS:
Distribution:-
The drug is 30% bound to plasma proteins.
Metabolism:-
Rocuronium is eliminated primarily by the liver with a small fraction (∼ 10%) eliminated in the 
urine.  It  is  taken  up  into  the  liver  by  a  carrier  mediated  active  transport  system.  The  putative 
metabolites 17-desacetyl rocuronium and 16N desallylrocuronium are pharmacologicaly inactive.
TABLE – I
Pharmacokinetics of rocuronium bromide
Age Group Volume of 
distribution at 
steady state (VDss 
ml/kg)
Clearance ml/Kg/
min
Elimination half; 
life (min)
Normal Adult 207 2.89 +/- 0.25 70.9 +/- 4.7
Elderly 399 +/- 122 3.67+/-1 97+/-69.1
Children 224 2.67 46 – 55
PHARMACODYNAMICS:
Neuromuscular Junction:
It produces non-depolarising muscle paralysis by competitive antagonism of acetylcholine at 
nicotinic receptors in the post synaptic membrane of the neuromuscular junction.  It  also has some 
prejunctional action.
Non depolarizing blockade is characterized by:-
a) Depression of twitch height
b) Fade with train of four or tetanic stimulation
c) TOF ratio < 0.7
d) Post tetanic facilitation and
e) Antagonism of block by anticholinesterases.
      It is 7-8 times less potent than vecuronium but has a faster onset. Paraylsis occurs first in the 
well perfused fast muscles and last in the diaphragm. Onset of block is faster but less intense at the 
adductor muscles of the larynx than at the adductor pollicis muscle while the diaphragm is affected 
later but recovers earlier than the adductor pollicis muscle.
The action of rocuronium can be increased in the presence of hypokalemia, hypermagnesemia, 
hypocalcemia, hypoproteinemia, dehydration, acidosis, hypercapnia and cachexia. Under hypothermic 
conditions the neuromuscular blocking effect of rocuronium, is increased and the duration prolonged.
Cardiovascular System:
The autonomic safety ratio  for  vagal  block  (3.0 – 5.0)  is  about  10 times  less  than that  of 
Vecuronium. Reports of slight to moderate increases in heart rate may be due either to rocuronium 
producing pain on injection or to its weak vagolytic effect. The heart rate increase may be controlled by 
the prior administration of fentanyl. Rocuronium in doses upto 0.6 mg/kg has cardiovascular effects 
that are negligible. At higher doses (0.9 – 1.2 mg/kg) increases in heart rate of 10 to 25% has been 
observed.
Histamine Release:
Rocuronium is not associated with clinical signs of histamine release in doses upto 5XED95.
Anaphylaxis / Anaphylactoid Reactions:
In terms of allergy rocuronium appears to have a good safety profile.
Central Nervous Sytem:
No effect as it does not cross the blood-brain barrier. No effect on Intracranial pressure.
Inra Ocular Pressure:
Minimal change in intraocular pressure. Appears to be safe for use in rapid-sequence induction 
of anesthesia for perforating eye injuries.
Placental Transfer:
Rocuronium does not cross the placenta in significant amounts.
Pseudocholinesterase Inhibition:
This may result in the prolongation of action of drugs that depend on cholinesterase for their 
metabolism like succinylcholine and mivacurium. The anticholinesterase activity of rocuronium is less 
than that of vecuronium.
SUCCINYL CHOLINE
It  is a Depolarising muscle ideal relaxant. It is the Relaxant for intubation since it is of quick 
onset and short duration of action.
Chemistry:
It is composed of two molecules of Acetyl choline linked back to back through Acetate – 
Methyl groups.
Molecular Structure
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Presentation
As a solution, it is available in 10ml vials containing 50mg/ml and in vials containing 100mg 
powder form.
Routes of administration
Intravenous
Intramuscular
Dose
ED95 - 0.51 – 0.63 mg/kg
Intubation dose - 1 – 1.5mg / kg
Onset of action - 30 to 60 sec.
Duration of action - 4 to 10 min.
Pharmacokinetics
Brief duration of action of succinyl choline is due to its rapid hydrolysis by plasma choline 
esterase  which  is  synthesized  in  liver.  It  is  metabolised   to  succinyl  mono  choline  which  is 
subsequently hydrolysed into succinic acid and choline.
Plasma cholinesterase influences duration of action of succinyl choline.  Plasma cholinesterase 
activity is decreased thereby prolonging succinyl choline effect in 
1) Liver disease
2) Organophosphorus compounds poisoning
3) Neostigmine,  metoclopramide co-administration
In healthy individuals,  some times,  action of succinyl  choline is  prolonged due to the presence of 
Atypical cholinesterase.
Dibucaine  No:
It is the percentage inhibition of enzyme activity                               (Plasma Cholinesterase) by  
Dibucaine. (local anaesthetic).
  Dibucaine  inhibits the activity of normal cholinesterase enzyme by 80% compared with only 
20% inhibition of activity with Atypical enzyme.
Pharmaco dynamics
Succinyl choline attaches to each of the alpha subunits of the nicotinic cholinergic receptor and 
mimics  the  action  of  Acetyl  Choline  thus  depolarizing  the  post  junctional  membrane.  Here,  the 
hydrolysis is slow resulting in sustained depolarization (opening) of the receptor ion channels.
Neuromuscular  blockade  develops  because  a  depolarized  post  junctional  membrane  cannot 
respond to subsequent release of Acetyl  Choline (Depolarizing Blockade).  It is otherwise called as 
Phase I Blockade.
Phase II  Blockade:
• Single large dose of succinyl choline (more than 2mg /kg IV)
• Repeated small doses of succinyl choline 
• Prolonged continous infusion 
may result in post junctional membranes that do not respond normally to Acetyl choline even when the 
post junctional membranes have become repolarized (desensitization blockade). Mechanism for this 
blockade is unknown
Adverse Effects
Cardiac Dysrhythmias
Sinus Bradycardia, Junctional Rhythm,  and sinus arrest can occur following administration of 
succinyl choline.
Hyperkalemia
It is common in patients with 
1) Muscular dystrophy
2) Third degree Burns
3) Denervation
4) UMN Lesions.
Myalgia
Post operative myalgia is common following administration of Succinyl choline. 
Myoglobinuria
Increased Intra Gastric Pressure 
 Risk of aspiration is more
Increased Intra Ocular Pressure- 
Increased intracranial pressure
Sustained skeletal muscle contraction – masseter spasm following co administration of halothane is  
not uncommon.
REVIEW OF LITERATURE
Rocuronium Bromide is a non deploarising muscle Relaxant with fast onset.
Dose of  Rocuronium used may influence the  onset  and duration of  action.   Literature  was 
reviewed  to  compare  intubating  conditions  with  Rocuronium  0.6mg/kg  and  0.9mg/kg  and  with 
suxamethonium  1.5mg/kg
1) CALUDIA A.Y. CHENG, CINDY ST AUN compared two doses of Rocuronium (0.6mg/kg 
and 0.9mg/kg) with suxamethonium 1.5mg/kg and concluded that Rocuronium 0.9mg/kg 
provides similar intubating conditions to suxamethonium.
2) Madhav S.Barve, Roopa Sharma compared intubating conditions and time course of action 
of Rocuronium & succinyl choline in paediatric patients and concluded that Rocuronium 
may be a suitable alternative to succinyl choline for intubation in paediatric age group.
3) Mazurek A J ; Hann S. compared Rocuronium versus succinylcholine for Rapid Sequence 
induction   and  concluded  larger  doses  of  rocuronium   may  be  an  alternative  to 
suxamethonium.
4) MC  Donald  PF,  Sanisbary  DA,  Evaluated  onset  time  and  Intubating  conditions  of 
rocuronium bromide  in  children  and  concluded  that  intubating  conditions  are  achieved 
faster with Rocuronium compared to other non depolarizing relaxants.
5) Cooper  R,  Mirakhur  RK, Clarke compared intubating  conditions  after  administration  of 
Rocuronium  and  suxamethonium  and  concluded  that  Rocuronium  0.6mg/kg  produces 
clinically acceptable intubating conditions at 60 seconds after induction with thiopentone 
5mg/kg
6) J.D. Crul & Colleagues observed clinically acceptable intubating conditions at 45 seconds 
with Rocuronium 0.6mg/kg
7) Stoddart compared intubating conditions of Rocuronium 0.6mg/kg with suxamethonium 1 
mg/kg  in  for  tonsillectomy  patients  and  onset  time  was  92  seconds  and  42  seconds 
respectively.
8) J. Viby - Mogenson observed the average clinical duration of intubating dose is shorter in 
children  than  adults  which  may  be  due  to  large  volume  of  distribution  of  control 
compartment in children.
9) Watanabe K, Chen K., et al (1991) described the pre and postsynaptic effects of org 9426 
(Rocuronium) during the onset and recovery from neuromuscular blockade. They found that 
the relaxant to have moderate potency with rapid onset time, intermediate duration of action 
and rapid recovery.
10) Meistelman C., et al (1994)4  found that onset time, intensity of blockade and duration of 
action were less at the larynx than at the adductor pollicis with 0.5mg/kg of rocuronium. 
The  onset  times  were  1.4+/-  0.1  and  2.4+/-0.2  minutes  at  the  laryngeal  muscles  and 
adductor pollicis, respectively. Maximum blockade was 77+/-5% and 98+/- 1% respectively 
(P=0.01) and time to 90% recovery was 22 minutes.
11) Jean  Paul  Cantineau,  et  al  (1994)5  found that  the  diaphragm is  more  resistant  than  the 
adductor pollicis to rocuronium 0.6 mg/kg. The onset time for muscle relaxation after 0.6 
mg/kg rocuronium was shorter  for  the  adductor  pollicis  muscle  than for  the  diaphragm 
(80+/- 20 Vs120 +/-62 sec). Times for 10% , 25%, 75% and 90% recovery of twitch height 
were 34+/- 10, 40+/-10, 56+/- 20 and 64+/-21 minutes, respectively for the adductor pollicis 
and significantly shorter for the diaphragm, 17+/-10, 23+/-9, 33+/-13, and 35+/-10 minutes 
respectively.  The  intubating  dose  of  0.6mg/kg  is  close  to  ED95  of  0.5mg/kg  for  the 
diaphragm.
12) Peter  M.C.  Wright.,  et  al  (1994)6   studied  the  onset   and  duration  of  rocuronium and 
succinylcholine at  the adductor pollicis  and laryngeal adductor muscles  in anaesthetized 
adults. They found that the onset of effect with succinylcholine was significantly more rapid 
at the laryngeal adductors (34+/-12 sec) than at the adductor pollicis (56+/-15 sec.) Onset 
times were similar at the two muscle groups with rocuronium 0.8 and 1.2mg (96+/-29 and 
74+/- 36 sec. with 0.8 mg/kg and 54+/-30 and 65+/- sec with 1.2mg/kg at the laryngeal 
adductors and the adductor pollicis, respectively.)  Rocuronium 0.4mg/kg had a more rapid 
effect at the laryngeal adductors than the adductor pollicis (92+/-29 sec. and 155+/- sec. 
respectively). They concluded that the laryngeal adductors are more resistant to the action of 
rocuronium than is the adductor pollicis. Onset of effect of rocuronium in doses greater than 
0.8mg/kg is similar to that of succinylcholine at the adductor pollicis but is significantly 
delayed compared with that of succinylcholine at the laryngeal adductors.
13) De Mey J.C., et al (1994)7 evaluated onset and intubating conditions of rocuronium bromide 
0.5, 0.75 or 0.9mg/kg in adult patients anaesthetized with propofol 2mg/kg and alfentanil 
0.5 to 1 µg/kg. They concluded that a dose of rocuronium equal to or larger than 0.6 mg/kg 
provides acceptable intubations at 60 seconds after administration.
14) Previs TH, Zahn P., et al (1994) Studied the ED95 dose of rocuronium bromide and the 
tracheal intubating conditions and time course of actions. They concluded the ED95  dose of 
rocuronium bromide was 0.3mg/kg and duration of action was 20 minutes.
15) Mirakhur  R.K.  et  al  (1994)8   compared  onset  and  intubating  conditions  of  rocuronium 
bromide  0.6mg/kg  and  suxamethonium  1mg/kg  in  adult  patients  anaesthetized  with 
thiopentone,  N2O  in  oxygen  and  small  doses  of  fentanyl.  Intubating  conditions  after 
rocuronium 0.6mg/kg were found to be clinically acceptable.(good or excellent)in 95% of 
patients at 60 seconds and in all patients at 90 seconds and in all patients at both times after 
suxamethonium. There was no significant  difference in  acceptable  intubating conditions 
between suxamethonium and rocuronium.
16) Scheiber G., et  al  (1996)9   Compared 0.6mg/kg rocuronium, 0.1 mg/kg vecuronium and 
0.5mg/kg atracurium in children during etomidate-fentanyl-nitrous oxide anaesthesia and 
found better intubating conditions at 60 seconds after rocuronium than 120 seconds after 
vecuronium or at 80 seconds after atracurium.
17) K.Barclay., et al (1997)17  assessed whether low doses of rocuronium improved conditions 
for  tracheal  intubation  during  induction  of  anaesthesia  with  propofol  2.5mg/kg  and 
alfentanil  10ug/kg.  They have  studied  three  groups.  One group received  saline,  second 
group rocuronium 0.1 mg/kg and the third group received 0.3mg/kg rocuronium and they 
assessed the intubating conditions as judged by jaw opening and laryngoscopy, position of 
the  vocal  cords  and  degree  of  straining  after  tracheal  intubation.  They  concluded  that 
injection of rocuronium 0.3mg/kg with propofol and alfentanil provided a high proportion 
of optimal intubating conditions.
18) Smith I, Saad Rs., et al (1998)14  Compared the onset of action and the intubating conditions 
after  rocuronium  0.6mg/kg  and  vecuronium   0.1mg/kg,  when  the  timing  of  tracheal 
intubation was determined by clinical  judgement alone like ease of ventilation,  jaw and 
upper airway tone. They concluded that time to laryngoscopy and completion of intubation 
was markedly shorter in the rocuronium group. Roucronium group also had significantly 
better intubating conditions.
19) Kirkegaard – Nielsen H., et al., (1999)10   studied rapid tracheal intubation with rocuronium 
using a probability based approach. 80 adult patients anaesthetized with fentanyl 2 µg/kg 
and  propofol  2mg/kg  randomly  received  rocuronium  0.0,  0.4,  0.8,  or  1.2  mg/kg 
(n=20/dose).  Laryngoscopy was initiated at 40 seconds aiming for intubation at 60 seconds. 
Doses giving 90 and 95% probability of successful intubation were calculated and found to 
be 0.83 and 1.04mg/kg respectively. Estimated times until first tactile train of four response 
after ED50 and ED95 doses were 32 and 46 minutes respectively. They concluded that after 
induction with fentanyl  and propofol,  rocuronium 1.04 mg/kg gives  95% probability of 
successful intubation at 60 seconds.
20) Andrews JI., et al (1999)15  Compared rocuronium and succinylcholine for rapid sequence 
induction of anaesthesia along with propofol and anesthesia was induced using propofol 
2.5mg/kg  followed  immediately  by  either  rocuronium  0.6mg/kg  or  1mg/kg  or 
succinylcholine 1mg/kg. Intubating conditions were assessed at one minute and intubation 
was performed. They concluded rocuronium 1mg/kg given along with propofol in a rapid 
sequence induction of anaesthesia is clinically equivalent to succinylcholine 1mg/kg.
21) Lam AM., et al (2000) 18  compared the onset and offset time and intubating condition after 
1min  obtained  with  rocuronium  bromide  0.6mg/kg  and  succinylcholine  1mg/kg  after 
induction  with propofol  and fentanyl.  They concluded that  rocuronium 0.6mg/kg,  when 
used with propofol and fentanyl  for  induction,  provides intubating conditions  similar  to 
succinycholine 1mg/kg at 1 minute.
MATERIALS AND METHODS
This study was conducted at Government Stanley Medical College And Hospital, Chennai.
After institutional approval and informed consent, 60 patients were enrolled in the study.
INCLUSION CRITERIA:-
∗ Children between 2 – 10 years
∗ ASA Physical status I & II
∗ For Elective surgeries posted under G.A.
EXCLUSION CRITERIA:-
∗ Infants
∗ Known / suspected difficult Intubation
∗ H/o any neuromuscular disorder
∗ Renal / Hepatic disorder
∗ Known allergy to drugs.
∗ Surgical procedures of very short duration.
∗ Patients receiving any medication known to interact with Neuromuscular blocking agent.
PRE OPERATIVE EVALUATION:-
In all the patients, Age, I.P.No, Body Weight, Baseline vital parameters were recorded. History 
regarding previous anaesthesia,  surgery, any significant medical illness, medications and allergy were 
recorded.
 Complete physical examination and Airway assessment was done.
Following laboratory Investigations were done:-
 Haemoglobin %
 Packed cell volume
 Urine – Albumin and sugar
 Chest X-Ray (in selective patients)
PREMEDICATION:
All children received syrup Triclofos 50mg/kg orally one hour before procedure.
INDUCTION OF ANESTHESIA:
After shifting the children to operation theatre, Intravenous line was secured using 22G Cannula 
in a vein in the dorsum of hand and Isolyte-P infusion was started .
Following monitors were connected to the patients:
1) Non Invasive Blood Pressure
2) Electro Cardiogram Monitor
3) Pulse Oximeter.
4) Precordial stethoscope
These patients were systematically randomized into three groups of twenty each.
Group – I (R6) Thiopentone 5mg/kg + Rocuronium 0.6mg/kg
Group –II (R9) Thiopentone 5mg/kg + Rocuronium 0.9mg/kg
Group-III (S) Thiopentone 5mg/kg + Suxamethonium 1.5mg/kg
Each patient was given Inj. Pentazocine 0.5mg/kg intravenously. After pre-oxygenating these 
children for three minutes, anaesthesia was induced with Inj. Thiopentone 5mg/kg 2.5% solution given 
over 15 seconds and followed by:-
 Inj. Rocuronium 0.6mg/kg (2xED95 ) 
Or
Inj. Rocuronium 0.9mg/kg (3xED95)
Or
Inj. Suxamethonium 1.5mg/kg
depending on the group given in less than 5 seconds. Intubation was performed in all children by an 
experienced anesthetist.(who did not know which relaxant was used for Intubation).
After  Intubation  and  observation  of  the  Intubating  conditions  and  hemodynamic  profiles, 
anesthesia was maintained with 40% oxygen and 60% Nitrous oxide using Jackson-Rees Circuit or 
closed circuit system with controlled ventilation.
In both rocuronium groups, if additional dose is required Inj. Rocuronium 0.15mg/kg was used. 
In suxamethonium group Inj. Atracurium 0.5mg/kg and then 0.2mg/kg doses  was repeated. And at the 
end of surgery, Reversal of Neuromuscular blockade was achieved with Inj. Neostigmine 50µg /kg and 
Inj. Atropine 20µg/kg.
No Regional blockade was given to any of these children before surgery.
The following observations were recorded:-
1) Intubating Conditions:
Intubating conditions were scored by a scoring system used by Mirakhar R.K., Cooper 
A.R. and Clarke R.S.J (Table II and Table III)
TABLE –II
Scoring of Intubating Conditions
Score Jaw Relaxation Vocal Cords Response to Intubation
0 Impossible to open Closed (Adducted) Severe Coughing
1 Open with difficulty Closing Mild Coughing
2 Moderate opening Moving Movement
Slight Diaphragm 
Movement
3 Easy Opening Open (Relaxed) No Movement
TABLE –III
GRADING
Intubating Conditions Score
Excellent 8-9
Good 6-7
Poor 3-5
Bad 0-2
The following parameters were recorded 
o Heart rate
o Systolic blood pressure
o Diastolic blood pressure
o Mean arterial pressure
before induction, during Intubation  and 1 min, 3 minutes and 5 minutes after intubation and clinical 
duration of the Intubating dose was recorded.
EVALUATION OF SIDE EFFECTS:
Patients  were monitored for  side effects  such as  signs  of  histamine release – wheal,  flush, 
bronchospasm, and bradycardia, pain on injection, etc.
STATISTICAL ANALYSIS:
The data was computed and all values were expressed as mean  +SD. The data was analysed 
using one way anova test, unpaired t test, chi-square test, mann-whitney u test, and kruskal wallis test 
as appropriate.
OBSERVATION AND RESULTS
The study was conducted on 60 patients randomly allotted into 3 groups as given below:-
TABLE –IV
DRUG DOSAGE AND SCHEDULE
Group Drug and Dose Sample Size Abbreviation
I Thiopentone 5mg/kg+
Rocuronium 0.6mg/kg
20 R6
II Thiopentone 5mg/kg+
Rocuronium 0.9mg/kg
20 R9
III Thiopentone 5mg/kg+
Suxamethonium 1.5mg/kg
20 S
TABLE –V
DEMOGRAPHIC PROFILE
Group –I Group – II Group –III P
Gender M/F 16/4 12/8 17/3 0.1
Age (Years)
Mean +SD
5.6+ 1.96 6.5+ 2.19 5.6+ 2.17 0.26
Weight(Kg)
Mean +SD
16+3.9 18.35+4.76 15.55+3.9 0.7
                      P>0.05 – Not significant
Statistical  Analysis  was done using chisquare test  for gender and for weight and age one way 
Anova test was used.  
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TRACHEAL INTUBATING CONDITIONS
The scores for Jaw Relaxation, vocal cord position and response to intubation and the total scores 
were compared between three groups.
TABLE –VI
JAW RELAXATION
Score Group I (R6) Group II (R9) Group III (S)
0 – Impossible to open - - -
1 – Open with difficulty - - -
2 – Moderate opening 15 7 2
3 – Easy opening 5 13 18
Mean + SD  2.16+0.44 2.65+0.49 2.89+0.32
Statistical Analysis was done using mann whitney u test showing 
Group I vs Group II P=0.002 - Significant
Group II vs Group III P= 0.07 – Not Significant
Group I vs Group III P=<0.0001 - Significant
TABLE –VII
VOCAL CORD POSITION
Score Group I (R6) Group II (R9) Group III (S)
0 – Closed - - -
1 – Closing - - -
2 – Moving Movement 13 3 1
3 – Open (Relaxed ) 7 17 19
Mean + SD  2.35+0.49 2.85+0.37 2.95+0.20
Statistical Analysis was done using mann whitney u test showing 
Group I vs Group II P=0.0008 - Significant
Group II vs Group III P= 0.30  -  Not Significant
Group I vs Group III P=<0.0001 - Significant
TABLE –VIII
RESPONSE TO INTUBATION 
Score Group I (R6) Group II (R9) Group III (S)
0-Severe Coughing / Bucking - - -
1 – Mild Coughing 1 - -
2 – Slight diaphragm movement 16 6 4
3 – No movement 3 14 16
Mean + SD  2.1+0.42       2.70+0.47 2.8+0.41
Statistical Analysis was done using mann whitney u test showing 
Group I vs Group II P=0.002 - Significant
Group II vs Group III P= 0.07 - Not significant
Group I vs Group III P=<0.0001 - Significant
TABLE –IX
TOTAL SCORE 
Intubation Score Group I (R6) Group II (R9) Group III (S)
8-9 Excellent 4 18 19
6-7 Good 15 2 1
3-5 Poor 1 - -
3 – Bad - - -
Statistical Analysis was done using mann whitney u test showing 
Group I vs Group II P=<0.0001 - Significant
Group II vs Group III P= 0.01      -  Significant
Group I vs Group III P=<0.0001 - Significant
HAEMODYNAMIC PROFILE
The heart rate, systolic pressure, diastolic blood pressure, mean arterial pressure were compared 
between three groups.
Heart Rate :
Group I (R6) - Table X
Group II (R9) - Table XI
Group III (S) - Table XII
Systolic Blood Pressure:
Group I (R6) - Table XIII
Group II (R9) - Table XIV
Group III (S) - Table XV
Diastolic Blood Pressure:
Group I (R6) - Table XVI
Group II (R9) - Table XVII
Group III (S) - Table XVIII
Mean Arterial Pressure 
Group I (R6) - Table XIX
Group II (R9) - Table XX
Group III (S) - Table XXI
Clinical  duration of the intubation dose:  
Group I (R6) - Table XXII
Group II (R9) - Table XXIII
Group III (S) - Table XXIV
RESULTS
1) Statistical Analysis showed that there was no significant difference between distribution of 
age, sex, and weight among study groups.
2) All children were succ      essfully intubated in 60 seconds without need for second attempt 
after administration of neuromuscular relaxant.
3) (a) Statistical analysis  showed that mean score for Jaw Relaxation was significantly higher 
in Group II (R9) and Group III (2.65+0.49 in Group II,  2.89+ 0.3 in Group III , and 2.16+ 
0.4 in Group I) .
(b) Mean score for vocal cord position was significantly higher in Group II & Group III 
when  compared  to  Group  I  (2.35+ 0.49,  2.85+  0.37  2.95+ 0.22  in  group  I,  II  &  III 
respectively.
(c) Mean score for response to intubation was significantly higher in Group II and Group III 
when  compared  to  Group  I.  (2.1+ 0.44,   2.7+  0.47,  2.8+0.41  in  Group  I,  II  &  III 
respectively)
(d) Mean total intubating score in Group II (R9) and Group III (S) were identical which is 
significantly higher than Group I.  (6.7+  0.86, 8.2+ 0.61, 8.7+ 0.57 in Group I,  II & III 
respectively).
4) Acceptable Intubating Conditions (Excellent and Good Scores) are observed in almost all 
the patients except in one patient in Group I (100% in Group II & Group III and 95% in 
Group I). 
But, Excellent Intubating Conditions were produced in most of the patients in Group II and 
Group III which was significantly higher than in Group I.
5) Statistical anaylsis showed that Mean heart rate, Systolic Blood Pressure, Diastolic Blood 
Pressure,  Mean Arterial  Pressure during Intubation in  Group I  (R6) was higher  than in 
Group II  and Group III.  (123.6+9.88,  121.2+7.93,  83+5.3,  93.5+5.94 in Group I and in 
Group  II  120.9  +11.114,  120.1+9.7,  79+7.85,  92.4+7.65)  and  in  Group  III  106.8+15, 
112+8.56, 75.6+6.28, 88.95+6.4 respectively)
6) Mean heart rate at the end of 5 minutes was higher in Group II (R9) compared to Group I 
(R6)  and  Group  III  (S).  (112.7+11.5,  116.64+11.5,  99.75+7.38)  in  Group  I,  II  and  III 
respectively)
7) Clinical duration of the intubating dose was significantly lower in Group III and among 
Group I & II, the duration was significantly longer in Group II. (20.35+2.08 minutes  in 
Group I 29.35 +2.64 minutes in Group II and in Group III  4.6+0.7 minutes).
DISCUSSION
Succinylcholine is an ideal muscle relaxant of choice for Intubation as it is an ultra short acting 
muscle  relaxant  producing  excellent  intubating  conditions  in  seconds  and  effect  wears  off  in  4-5 
minutes  usually.  But  it  has  got  potential  adverse effects  such as  Asystole,  Bradycardia,  malignant 
hyperthermia, Raised Intraocular pressure, Raised Intra gastric pressure, Post operative muscle pain. 
Hyperkalemia  etc.  and  reports  of  sudden  cardiac  arrests  in  patients  with  undiagnosed  muscular 
dystrophy. Therefore, need exists for a non depolarizing muscle relaxant with a fast onset of action.
Rocuronium is a new steroidal non deploarising muscle relaxant with rapid onset of action and 
Rapid Onset is believed to be primarily due to its low potency and duration of action is dose dependent. 
It is short acting with a dose of 0.3mg/kg (1xED95) and Intermediate duration of action with 0.6-0.9mg/
kg when more than 1mg/kg is used for Intubation, onset is very quick (less than 45 seconds) but the 
duration of action is prolonged (more than 1 hour).
In this study we aimed to evaluate the intubating conditions in 60 seconds using smaller doses 
of Rocuronium (0.6mg/kg  (2xED95  ) & 0.9mg/kg (3xED95) and compared them with the intubating 
conditions after 1.5mg/kg of suxamethonium.
There  have  been  several  adult  studies  comparing  various  doses  of  Rocuronium   with 
Suxamethonium mimicking rapid sequence induction of Anaesthesia.
We wanted to confirm that Rocuronium is a suitable alternative to suxamethonium even in 
pediatric age group because the onset time and duration of action are some what different in children 
compared with adults.
In  the  study  conducted  by  R.Cooper  95%  patients  had  developed  acceptable  intubating 
conditions at 60 seconds with Rocuronium 0.6mg/kg when the patients were induced with Thiopentone 
5mg/kg and Fentanyl 1-3 µ g/kg.
Similarly J.F crul  and  colleagues  observed clinically acceptable  intubating conditions  at  45 
seconds with Rocuronium 0.6mg/kg in patients induced with propofol and alfentanyl 20 µ g/kg.
In  the  present  study.  Intubating  conditions  were  excellent  with  Suxamethonium group  and 
Rocuronium 0.9mg/kg group. When comparing with suxamethonium,  Rocuronium  0.6mg/kg was 
inadequate.
We did not use Atropine with induction as we wanted to observe the Intubation response and 
vagolytic properties of Rocuronium and                Atropine 0.1mg/ml was diluted and kept ready and 
one patient in Suxamethonium group required  0.2mg bolus once.
The average clinical duration of Rocuronium in pediatric patients is shorter than in adults (26+ 
7 min observed by J. Viby – Moganson). It may be due to larger volume of distribution of central 
compartment (V1) in pediatric population than in adults.
In our study it was 20.35 +/- 2.08 minutes  for Group I and 29.35 +/- 2.64 minutes in Group II, 
and  4.60+/- 0.7 minutes in Group III.
Shorter duration of action for both groups in our study may be due to avoidance of Inhalational 
agents and potent opioids No Regional Anaesthesia like Caudal Block was given to any patients in the 
beginning of surgery.
Agoston S et al (1995) studied the onset time and Intubating conditions of Rocuronium bromide 
and declared that since there is no parellel correlation between adductor pollicis and laryngeal muscle 
Relaxation,  Neuromuscular  transmission  monitoring  is  probably  obsolete  in  regard  to  intubating 
conditions.
Cantineau JP, et al (1994)5  studied the neuromuscular effect of rocuronium on the diaphragm 
and adductor pollicis muscles in anaesthetized patients and showed that the onset time for diaphragm is 
slower than for adductor pollicis.
Wright PMC, Caldwell JE, Miller RD., et al (1994)6  studied onset and duration of rocuronium 
and succinylcholine at the adductor pollicis and laryngeal adductor muscles in anaesthetized patients 
and showed that onset of action of rocuronium is slower at the diaphragm than at the adductor pollicis, 
but faster at the laryngeal muscles than at the adductor pollicis.
We did not monitor the development of neuromuscular block as it has been clearly shown that 
there  is  poor  correlation  between  onset  time  measured  at  the  adductor  pollicis  and  the  quality  of 
intubating  conditions.  So,  for  more  than  40  years  authors  have  abandoned  instrumental  means  to 
evaluate laryngoscopy and intubating conditions and are using scales which assess clinical criteria only 
to assess the quality of tracheal intubation. The scale used in the study was used originally by Cooper et 
al. in their study and is recommended for studies with neuromuscular blockers8.
HAEMODYNAMIC CHANGES
Thiopentone causes fall in Blood Pressure and Reflex tachycardia.
Pancuronium has vagolytic property and causes hypertension and tachycardia. Vecuronium has 
no such property and hence provides stable haemodynamics. Rocuronium has got vagolytic properties 
with larger doses.
In  our  study mean heart  rate,  mean systolic,  mean diastolic,  and mean Arterial  pressure at 
intubation  were   higher  in  Rocuronium 0.6mg/kg  group  when  compared  to  other  groups,  though 
statistically insignificant.
Mean Increase in heart rate after 5 minutes was more in Rocuronium 0.9mg/kg Group  when 
compared to other groups. 
ADVERSE EFFECTS
The adverse effects  looked for were evidences of Histamine Release like Flushing,  Wheal, 
Bronchospasm and Hypotension and pain on injection.
Cooper R., et al (1992) found that there were no significant changes in heart rate or Arterial 
Pressure after Rocuronium 0.6mg/kg and there was no evidence of Histame Release.
In our study, No signs of histamine release was noted in any of the patients.
One patient of suxamethonium group developed bradycardia which was corrected with bolus 
dose of Atropine.
SUMMARY
1) Both  doses  of  Rocuronium  0.6mg/kg  and  0.9mg/kg  produced  acceptable  intubating 
conditions (good or excellent) in one minute.
2) But,  Excellent  intubating  conditions  identical  to  suxamethonium  was  provided  with 
rocuronium 0.9mg/kg group.
3) Duration of action was significantly more in Rocuronium 0.9mg/kg group when compared 
to suxamethonium.
4) No signs of Histamine release was observed in any of the patients.
5) Increase in Heart rate and Blood pressure at intubation was more in Rocuronium 0.6mg/kg 
group  compared to other groups.
CONCLUSION
Rocuronium  0.9mg/kg (3xED95) can be used as an alternative ideal agent to suxamethonium 
for intubation in children.  But while choosing Rocuronium as an alternative to suxamethonium 
factors such as intubation difficulty and surgical duration should be considered against the potential 
side effects of suxamethonium.
BIBLIOGRAPHY
1) Clandia A.Y. Cheng, Cindy S.T. Aun – comparison of Rocuronium and Suxamethonium for 
Rapid tracheal intubation in children.
2) Sparr HJ Luga TJ, comparison of Rocurnium and suxamethonium with Thiopentone for 
elective cases.
3) Susan Woeltel – clinical duration of Anaesthesia.
4) Wierda J.M.K.H., De Wit A.P.M. Kuizenga K, Agoston S.
Clinical observations on the neuromuscular blocking action of org  9426, a new steroidal 
non-depolarizing agent.
British Journal of Anaesthesia 1990;64:521-523
5) Meilstelman C., Plaud B., Donati F.
A comparison of neuromuscular blocking effects of rocuronium bromide at the adductor 
pollius and laryngeal muscles.
European Journal of Anaesthesiology 1994; 11(Suppl.9) : 33-36
6) Cantineau JP, Porte F d’ Honneur G et al
Neuromuscular effect of rocuronium on the diaphragm and adductor pollucis muscles in 
anaesthetized patients.
Anaesthesiology, 1994;81:585-590.
7) Wright P.M.C; James E.Cardwell, Ronald D. miller 
Onset and duration of rocuronium and succinylcholine at the adductor pollicis and laryngeal 
adductor muscles in anaesthetized humans.
Anaesthesiology 1994;81:1110-1115.
8) De Mey JC., Debrock M., RollyG
Evaluation of onset and intubation conditions of rocuronium bromide
European Journal of Anaesthestology 1994; 11 (Suppl.9): 37-40
9) Mirakhur R.K., Cooper A.R. and Clarke R.S.J.
Onset and intubating conditions of rocuronium bromide compared to those of 
suxamethonium.
European Journal of Anaesthesiologyu 1994; (Suppl. 19): 41-43
10) Scheiber G., Ribeiro P.C., Marichal A., et al.
Intubating conditions and onset of action after rocuronium, vecuronium and atracurium in 
children.
Anaesth. Analg. 1996; 83:320-324.
11) Kirkegaard Nielson H., James E. Caldwell, Peter D. Berry 
Rapid tracheal intubation with rocuronium.
Anaesthesiology 1999;91:131-136.
12) Andrews JI, Kumar N, Van den Brom RH, Oikkola KT, Roest GJ, Wright PM A large 
simple randomized trial of rocuronium versus succinylcholine in rapid sequence induction 
of anaesthesia along with propofol.
Acta Anaesthesiol Scand. 1999 Jan; 43(1): 1-8
13) K.Barclay, K.Eggers and T.Asai
Low dose rocuronium improves condition for tracheal intubation after induction of 
anaesthesia with propofol and alfentanil.
British Journal of Anaesthesia 199;78:92-94
14) Lam AM, Pavlin EG, Visco E and Taraday J.
Rocuronium versus succinylcholine – atracurium for tracheal intubation and maintenance 
relaxation during propofol anaesthesia
J Clin Anaesthesia 2000 Sep; 12(6): 449-53.
15) Agoston S.
Onset time and evaluation of intubating conditions: rocuronium in perspective European 
Journal of Anaethesiology 1995;12 (Suppl. 11) 31-7
16) Donati F.
Onset of action of relaxants
Canadian Journal of Anaesthesia 1988;35:552-8
17) Cooper R., Mirakur R.K. Clarke R.S.J.  and Boules Z
Comparison of intubating conditions after administration of rocuronium and 
suxamethonium
British Journal of Anaesthesia 1992;69: 269-273
18) Cooper R, Mirakhur R.K. Maddineni V.R.
Neuromuscular effects of rocuronium bromide during fentanyl and halothane anaesthesia.
Anaesthesia 1993; 48:103-105
A study comparing two doses of Rocuronium with Suxamethonium for Intubation in children in 
60 seconds.
PROFORMA
1. Name Age/Sex: P NO.   Weight
Diagnosis: Surgery Performed:
Preop Assessment :
Investigations: O/E:
Premedication – Syrup Triclofos 50mg per kg orally one hour before procedure
Shifting to O.T.
IV line Securing
Analgesia used – Inj. Pentazocine 0.5mg / kg IV
Induction – Inj. Thiopentone 5mg/kg
Muscle relaxant used
Group I - Inj. Rocuronium 0.6mg/kg
Group II - Inj. Rocuronium 0.9mg/kg
Group III - Inj. Suxamethonium 1.5mg/kg
Intubation at 60 sec.
Intubation score - Cooper Scoring System
Score Jaw Relaxation Vocal Cards Response to Intubation
0 Impossible to Open Closed (Adducted) Severe Coughing or 
Bucking
1 Open with Difficulty Closing Mild Coughing
2 Moderate Opening Moving Movement Slight diaphragm Movement
3 Easy Opening Open (Relaxed) No Movement
Intubation Score 8-9 - Excellent
6-7 - Good
3-5 - Fair
<3 - Poor
No. of Attempts:
Hemodynamic Response to Intubation
Time Baseline Induction Intubation 1 min. 3 min. 5 min.
HR
Spo2
BP
Clinical duration of intubating dose :
Adverse Effects noted :
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